New York, USA – Creative Biolabs, a world leading immunotherapy service provider, who is known for its largest collection of CAR products of different generations targeting various biomarkers, now provides a series of products for disease-specific CAR-T therapy development.
Chimeric antigen receptor (CAR)-engineered T cell therapy is one of the most popular research directions in the field of cancer immunotherapy, which artificially modifies the T lymphocytes of cancer patients through genetic engineering technology to generate tumor-specific CAR-T cells in vitro, and then introduce them back into the patient to attack cancer cells. Up to now, CAR-T therapy has achieved excellent results in the treatment of blood cancers, such as leukemia, lymphoma. Meanwhile, it also presents enormous potential in the solid tumors field.
Aiming to assist academic and industrial clients with their research, preclinical investigation and clinical stage development, Creative Biolabs has established a comprehensive One-Stop CAR-T Cell Development Platform that covers the entire development process ranging from biomarker identification & selection, high affinity scFv generation, CAR design & construction to CAR-T preclinical in vivo assay.
Based on the complete technology platform and a rich-experienced expert team, Creative Biolabs is committed to CAR-T therapy development for the research of a number of diseases, including but not limited to Lymphoma, Leukemia, Carcinoma, Sarcoma, Blastoma, Glioma, Germ Cell Tumor. CAR vector products, TCR vector products, and CAR viral particles are also available at Creative Biolabs.
“Thanks to our consistent efforts in the past 10 years in the CAR-T field, we have accumulated much valuable experience by different cases from our global clients, and, therefore, have created a mature service system to help clients obtain a satisfying result in fast turnaround time.” Introduced by the senior scientist at Creative Biolabs, “We can guarantee customers high-quality vectors and viral particles with globally fast delivery.”
Apart from CAR-T therapy services, Creative Biolabs also offers one-stop solution to TCR development and vaccine development. More information can be found at https://www.creative-biolabs.com/car-t.
About Creative Biolabs
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.